Quantcast

Baxter in deal with Dorizoe for expand generic injectables pipeline

Baxter International has entered into an agreement with a global contract research and development (R&D) organization, Dorizoe Lifesciences Limited (Dorizoe), to speed up the development of more than 20 generic injectable products–including anti-infectives, oncolytics and cardiovascular medicines.

Dorizoe will work with Baxter to perform certain product development activities, and Baxter will hold worldwide manufacturing and commercialization rights. Financial terms of the agreement were not disclosed.

“This partnership extends Baxter’s growing pipeline of generic injectables, further strengthening our portfolio with a broad range of high-quality essential medicines,” said Robert Felicelli, president, Pharmaceuticals, Baxter. “We look forward to working with Dorizoe to bring their highly skilled technical expertise together with Baxter’s manufacturing leadership and hospital channel strength to better serve the needs of patients around the world.”

Baxter estimates that the global sterile generic injectables segment is more than $40 billion, with a compound annual growth rate of approximately 10 percent (2010 – 2015). Baxter currently participates in a niche portion of the segment, producing difficult-to-manufacture oncology drugs and standard-dose, ready-to-use premixed injectable products.

Leave a Reply

Your email address will not be published. Required fields are marked *